Of the chemokines we were able to analyze, GROα (CXCL1), IP10 (CXCL10), MCP1 (CCL2), MIP1α (CCL3), MIP1β (CCL4) and MIP2 (CXCL2) were increased in AD serum samples and alleviated in response to GP supplementation in both prevention and intervention groups. This evidence concerns the gene CCL3 and Alzheimer disease.